We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Cardiolipin (IgG and IgM) antibodies

General information

Found in the anti-phospholipid syndrome, which may be primary or occur as a secondary complication of SLE. Elevated levels are significantly associated with the presence of both venous and arterial thrombosis, thrombocytopaenia, and recurrent fetal loss.

Specimen transport: At room temperature

Repeat frequency: The British Society for Standards Clinical Haematology guidelines requires anti-cardiolipin, lupus anticoagulant or  Anti-β2-glycoprotein I  to be present on two or more occasions at least 12 weeks apart to diagnose anti-phospholipid syndrome antibody.

Special precautions: None

Laboratory information

Normal reference range: 0 to 19.9 GPLU/MPLU /mL (both IgG and IgM class antibodies)

Volume and sample type: 7ml clotted blood

Method: FEIA (Fluoroenzyme Immunoassay)

Turnaround time (calendar days from sample receipt to authorised result): Median - 1, 95th percentile - 4

EQA scheme: UK NEQAS Scheme for Phospholipid antibodies

Clinical information

Indications for the test: Thrombosis, miscarriage

Factors affecting the test: False positives in infections

Clinical workstation reference: CARDIOLIPIN


(Last updated July 11th 2016)